Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSPE.L Regulatory News (SPE)

  • There is currently no data for SPE

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Amendment to the Terms of Convertible Loan Stock

8 Dec 2017 07:00

RNS Number : 7627Y
Sopheon PLC
08 December 2017
 

Embargoed Release: 07:00hrs Friday 8 December

 

 

SOPHEON PLC

 

AMENDMENT TO THE TERMS OF CONVERTIBLE LOAN STOCK

 

Sopheon plc ("Sopheon", the "Company" or the "Group") announces that it has reached agreement with the holders of its remaining £1.94m of convertible unsecured loan stock (the "Loan Stock") to convert it into equity by the end of 2017. 

 

As previously announced, in 2009 and 2011, the Company issued a total of £2m of Loan Stock to a group of investors including members of the Board and senior management team. The Loan Stock, which carries an interest coupon at a rate of 8 percent per annum, is currently due to mature on 31 January 2019, and has a conversion price of 76.5p per ordinary share of 20p each in the Company ("Ordinary Shares"). Board members with an interest in the Loan Stock are Barry Mence (£640,000), Andrew Michuda (£45,000), Arif Karimjee (£27,000) and Stuart Silcock (£200,000). Rivomore Limited, a current substantial shareholder in the Company, has an interest in the Loan Stock of £640,000.

 

Proposals have yesterday been put to the holders of the Loan Stock that would reconstitute the instrument such that it would automatically convert to equity on 22 December 2017, at the conversion price stated above, resulting in the issue of 2,535,947 new Ordinary Shares. This change will improve the profile of the Group's year end balance sheet and simplify the capital structure, as well as eliminating the interest charge going forward. In conjunction with this proposed amendment, a one-off payment of 8 percent of the face value of the Loan Stock will be made to holders of the Loan Stock in cash amounting to approximately £155,000, in recognition of the loss of their interest and repayment rights as a result of the early conversion. Irrevocable undertakings have been received from holders representing almost £1.7m of the Loan Stock, being over 85 per cent of the Loan Stock in issue, to vote in favour of a resolution to authorise the amendment of the Loan Stock instrument as described above at a forthcoming meeting of the Loan Stock holders on 22 December 2017 (the "Meeting").

 

The modification of the terms of the Loan Stock constitutes a related party transaction for the purposes of AIM Rule 13. In accordance with the AIM Rules for Companies, Daniel Metzger, as the director independent with respect to this transaction, having consulted with the Company's Nominated Adviser, finnCap Limited, considers that the amendment to the terms of the Loan Stock are fair and reasonable insofar as the Company's shareholders are concerned.

 

Following formal approval by Loan Stock holders at the Meeting, application will be made for the 2,535,947 new Ordinary Shares to be admitted to trading on AIM, and dealings expected to commence on 27 December 2017. The new Ordinary Shares will rank pari passu with the Company's existing Ordinary Shares. A further announcement will be made following the Meeting.

 

 

Sopheon's Chairman, Barry Mence said: "I am delighted and grateful that our convertible loan stock holders have continued to show such solid support for the Company, as they have through the last several years of our development as a business. With these changes we will enter 2018 with a clearer capital structure and an enhanced balance sheet."

 

 

For further information contact:

Barry Mence, ChairmanArif Karimjee, CFO

Sopheon plc

+ 44 (0) 1276 919 560

Carl Holmes / Giles Rolls (corporate finance)

Mia Gardener / Camille Gochez (corporate broking)

finnCap Ltd

+ 44 (0) 20 7220 0500

 

About Sopheon. Sopheon (LSE: SPE) partners with customers to provide complete enterprise innovation management solutions including software, expertise, and best practices, that enable them to achieve exceptional long-term revenue growth and profitability. Sopheon's Accolade solution provides unique, fully-integrated coverage for the entire innovation management and new product development lifecycle, including strategic innovation planning, roadmapping, idea and concept development, process and project management, portfolio management and resource planning. Sopheon's solutions have been implemented by over 250 customers with over 60,000 users in over 50 countries. Sopheon is listed on AIM, operated by the London Stock Exchange. For more information, please visit www.sopheon.com

 

The information communicated within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014.

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCEADAXELDXFAF
Date   Source Headline
11th Apr 20167:00 amRNSDirectors Options and Shareholding
21st Mar 20167:00 amRNSAmendment to Terms of Convertible Loan Stock
17th Mar 20167:00 amRNSFinal Results
21st Jan 20168:29 amRNSAccolade Release 10.2
8th Jan 20167:00 amRNSTrading Update and Board Change
20th Oct 20159:33 amRNSDirector Dealing
19th Oct 20157:00 amRNSDirector Dealing
9th Oct 20153:41 pmRNSDirector Dealing
9th Oct 20151:12 pmRNSDirector Dealing
2nd Oct 20153:39 pmRNSDirector Dealing
23rd Sep 20157:00 amRNSAccolade Release 10.1
27th Aug 20157:01 amRNSHalf Yearly Report
1st Jul 20157:00 amRNSDirector Shareholding
10th Jun 20151:44 pmRNSResult of AGM
10th Jun 20157:00 amRNSAGM Statement
2nd Jun 20157:00 amRNSAccolade 10.0 release
15th May 20153:10 pmRNSNotice of AGM
7th May 201511:40 amRNSDIRECTOR SHAREHOLDING
23rd Apr 201511:10 amRNSDirector Shareholding
20th Apr 201511:43 amRNSDirector Shareholding
13th Apr 20152:03 pmRNSHolding(s) in Company
10th Apr 201511:05 amRNSHolding(s) in Company
8th Apr 20157:00 amRNSDELISTING FROM ALTERNEXT AMSTERDAM
19th Mar 20157:00 amRNSFinal Results
20th Feb 20157:00 amRNSSopheon Releases Accolade® 9.3
5th Feb 20154:12 pmRNSChange of Registered Office
28th Jan 20157:00 amRNSTrading Update
19th Dec 201410:30 amRNSResult of General Meeting
12th Dec 20143:00 pmRNSTrading Update
2nd Dec 20144:00 pmRNSProposed Share Subdivision
2nd Dec 20147:00 amRNSDirector/PDMR Shareholding
27th Oct 20144:15 pmRNSDirector/PDMR Shareholding
22nd Oct 20143:45 pmRNSDirector/PDMR Shareholding
21st Oct 20147:00 amRNSDirector/PDMR Shareholding
17th Oct 20141:50 pmRNSDirector/PDMR Shareholding
10th Oct 201411:15 amRNSResult of GM and Further re Share Consolidation
24th Sep 20147:00 amRNSAccolade 9.2 Release
12th Sep 20147:00 amRNSShare Consolidation
28th Aug 20147:00 amRNSHalf Yearly Report
11th Jun 201412:20 pmRNSResult of AGM
11th Jun 20147:00 amRNSAGM Statement
2nd Jun 20147:00 amRNSAmendment To The Terms Of Convertible Loan Stock
22nd May 20147:00 amRNSAlternext Amsterdam
1st May 20147:00 amRNSInterim Management Statement
22nd Apr 20147:01 amRNSSopheon Delivers Accolade Release 9.1
11th Apr 20147:00 amRNSWind Down Of Alternext Amsterdam
20th Mar 20147:01 amRNSTotal Voting Rights
20th Mar 20147:00 amRNSPreliminary Results
6th Mar 20147:00 amRNSNew Debt Facility
29th Jan 20148:00 amRNSTrading Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.